Evidence map›Paper›PMID 34887643›Full record

ReviewWorld journal of gastroenterology2021

Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.

Mina S Makary, Stuart Ramsell, Eric Miller, Eliza W Beal, Joshua D Dowell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mina S MakaryDepartment of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States. mina.makary@osumc.edu.
Stuart RamsellDepartment of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
Eric MillerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
Eliza W BealDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
Joshua D DowellDepartment of Radiology, Northwest Radiology, St. Vincent Health, Indianapolis, IN 46260, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an overall five-year survival rate of less than twenty percent. For patients with unresectable disease, evolving liver-directed locoregional therapies provide efficacious treatment across the spectrum of disease stages and

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsHumansTreatment OutcomeBland embolizationChemoembolizationHepatocellular carcinomaLocoregional therapyRadioembolizationThermal ablationTransarterial embolization

Identifiers

PMID34887643
PMCPMC8613749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.